Zoledronic acid exhibits radio-sensitizing activity in human pancreatic cancer cells via inactivation of STAT3/NF-κB signaling
Authors You Y, Wang Q, Li H, Ma Y, Deng Y, Ye Z, Bai F
Received 22 January 2019
Accepted for publication 9 April 2019
Published 4 June 2019 Volume 2019:12 Pages 4323—4330
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Aruna Narula
Peer reviewer comments 2
Editor who approved publication: Dr Takuya Aoki
Yanjie You*,1 Qiang Wang,2,* Haijun Li,3,* Yuhong Ma,1 Yanhong Deng,1 Zhengcai Ye,4 Feihu Bai1
1Department of Gastroenterology, Ningxia Hui Autonomous Region People’s Hospital, Yinchuan, Ningxia Hui Autonomous Region 750021, People’s Republic of China; 2Department of Science and Education, Ningxia Hui Autonomous Region People’s Hospital, Yinchuan 750021, People’s Republic of China; 3Department of Radiation Oncology, The Second People’s Hospital of Neijiang, Neijiang, Sichuan 641003, People’s Republic of China; 4Endoscopy Center, Ningxia Hui Autonomous Region People’s Hospital, Yinchuan 750021, People’s Republic of China
*These authors contributed equally to this work
Background: Although pancreatic cancer is typically radio-sensitive, local treatment failure and metastasis are commonly caused by the development of resistance to radiotherapy. In the current study, the radio-sensitizing actions of zoledronic acid (ZOL) on pancreatic cancer cells were investigated.
Materials and methods: Three human pancreatic cancer cell lines were exposed to ZOL, ionizing radiation (IR), or a combination of both, and the effects of the respective drug regimens on cell proliferation and invasion were examined.
Results: Combined treatment with low doses of ZOL plus IR efficiently increased cell death and attenuated cell invasion compared with the individual use of ZOL or IR. These effects of ZOL were associated with inactivation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor-κB (NF-κB).
Conclusion: Collectively, these data suggest that ZOL in combination with IR is a promising therapeutic strategy for enhancing radio-sensitivity in pancreatic cancer cells via downregulation of the STAT3/NF-κB signaling pathway.
Keywords: pancreatic cancer, radio-resistance, zoledronic acid, radio-sensitizing effects
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]